Kazakhstan weighs commodity export duties to narrow budget gap
Taxes on sulfur, coal and ferroalloys, along with ores and concentrates of copper and iron, are among those that are expected to yield the most revenue.
(via TheNewswire)
Winnipeg – TheNewswire - August 15 2024 - Cytophage Technologies Ltd. (TSXV:CYTO) (“Cytophage” or the “Company”), the only publicly traded phage company that is focused on bacteriophage solutions for both animal health and human health, is pleased to announce the launch of a simplified application option for bacteriophages that can treat multiple types of bacteria, such as E. coli and Salmonella, throughout the lifecycle of a chicken. The lyophilized tablets were first developed and tested in the spring of 2024 and are now being targeted for wider application.
The lyophilized phage tablets are designed to provide an alternative to the liquid form commonly used in phage therapy. This lyophilized (freeze-dried/stabilized) product represents a technological breakthrough, offering increased flexibility, stability, and application versatility. This innovative development is in direct response to Cytophage working with the poultry industry on phage products with the goal to reduce the use of broad-spectrum antibiotics and replace them with targeted phages.
Product Highlights:
Ready-to-use, dissolves easily in water to simplify the process for the farmer.
Dose controlled, can simply be added to the specified water levels (see Image 1).
Temperature stable, does not require a cold chain making it easily usable in hotter climates such as South-East Asia.
Lightweight packaging, easily portable to the barn.
Cytophage CEO, Dr. Steven Theriault, commented: ”The importance of eliminating the need for a cold chain cannot be overstated. Offering phages in lyophilized form represents a competitive advantage over other phage producers who have only liquid products that require refrigeration. Our innovative manufacturing increases our products’ heat tolerance and shelf-life.”
Image 1: Lyophilized phage tablets easily dissolve in the specified water levels
Cytophage anticipates leveraging this innovation globally across all existing and pending product lines. The Company believes it is currently the only phage company worldwide capable of delivering a lyophilized phage product at scale, without significantly increasing costs for consumers.
For further information please contact:
Heather Medwick
Chief Operating Officer
431 388 8873
Cytophage Investor Alerts: https://cytophage.com/subscribe/
About Cytophage Technologies
Cytophage Technologies (TSXV:CYTO) is a pioneering biotechnology company dedicated to bacteriophage research, product development and commercialization. Committed to addressing the global challenge of antibiotic resistance, Cytophage advances innovative products that harness the power of bacteriophages to combat bacterial infections affecting human health, animal health, and food security.
Cautionary Statement on Forward-Looking Information
This news release contains “forward-looking information” and “forward-looking statements” (collectively, “forward-looking statements”) within the meaning of the applicable Canadian securities legislation. All statements, other than statements of historical fact, are forward-looking statements and are based on expectations, estimates and projections as at the date of this news release. Any statement that involves discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, assumptions, future events or performance (often but not always using phrases such as “expects”, or “does not expect”, “is expected”, “anticipates” or “does not anticipate”, “plans”, “budget”, “scheduled”, “forecasts”, “estimates”, “believes” or “intends” or variations of such words and phrases or stating that certain actions, events or results “may” or “could”, “would”, “might” or “will” be taken to occur or be achieved) are not statements of historical fact and may be forward-looking statements. Forward-looking statements involve known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements of Cytophage to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements. Factors that could cause actual results to differ materially from those anticipated in these forward-looking statements are
described under the caption “Risk Factors” in Cytophage’s Filing Statement dated January 30, 2024, which is available for view on SEDAR+ at www.sedarplus.ca. These risks include but are not limited to, the risks associated with the bacteriophage industry, such as operational risks in development or capital expenditures, the uncertainty of extensive regulatory approval requirements, government regulations, protection of intellectual property, product liability and rapid technological advancements. Forward-looking statements contained herein are made as of the date of this press release, and Cytophage disclaims, other than as required by law, any obligation to update any forward-looking statements whether as a result of new information, results, future events, circumstances, or if management’s estimates or opinions should change, or otherwise. There can be no assurance that forward-looking statements will prove to be accurate, as actual results and future events could differ materially from those anticipated in such statements. Accordingly, the reader is cautioned not to place undue reliance on forward-looking statements.
Neither the TSXV nor its Regulation Services Provider (as that term is defined in the policies of the TSXV) accepts responsibility for the adequacy or accuracy of this news release.
Copyright (c) 2024 TheNewswire - All rights reserved.
